Stanley Margaret A
Department of Pathology, Cambridge, UK.
Expert Rev Vaccines. 2003 Jun;2(3):381-9. doi: 10.1586/14760584.2.3.381.
Virus-like particle (VLP) subunit vaccines composed of the major capsid protein L1 of the genital human papillomaviruses (HPVs) are now in Phase III clinical trials. The vaccines are immunogenic and safe and early results indicate efficacy. VLPs induce strong cell-mediated as well as humoral immune responses and chimeric VLPs including an HPV early protein may have therapeutic potential. Polynucleotide and recombinant viral vaccines encoding nonstructural viral proteins show therapeutic and prophylactic efficacy in animal models and are candidate immunotherapies for established low-grade benign genital infections. Vaccines designed to elicit cytotoxic T-lymphocytes specific for the HPV oncoproteins E6 and E7 show immunogenicity and efficacy in transplantable tumor models in rodents. In Phase I and II trials these vaccines are immunogenic and safe but show limited efficacy.
由生殖器人乳头瘤病毒（HPV）主要衣壳蛋白L1组成的病毒样颗粒（VLP）亚单位疫苗目前正处于III期临床试验阶段。这些疫苗具有免疫原性且安全，早期结果表明其具有疗效。VLP可诱导强烈的细胞介导免疫反应和体液免疫反应，包含HPV早期蛋白的嵌合VLP可能具有治疗潜力。编码病毒非结构蛋白的多核苷酸疫苗和重组病毒疫苗在动物模型中显示出治疗和预防效果，是已确诊的低度良性生殖器感染的候选免疫疗法。旨在引发针对HPV癌蛋白E6和E7的细胞毒性T淋巴细胞的疫苗在啮齿动物的可移植肿瘤模型中显示出免疫原性和疗效。在I期和II期试验中，这些疫苗具有免疫原性且安全，但疗效有限。
